Notify Therapeutics focuses on the initial ovarian follicle development in the hormone-independent phase to help infertile women who do not benefit from today’s standard hormone treatment. Self-described as a first-in-class female fertility treatment.

Notify Therapeutics

Notify Therapeutics | 678 followers on LinkedIn. Novel treatment paradigm for infertile women. | Through targeting of the early and hormone-independent phase of egg maturation, we aim at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy.

Jacob Falck Hansen

Biotech Entrepreneur

Henrik Stage

Principal | Lundbeckfonden BioCapital | Venture Capital | Business Development | Life Sciences | PhD |

Kevin Dolowy Dalgaard

Senior Research Scientist, Notify Therapeutics

Kristina Byskov

Great news for CEO and founder of Notify Therapeutics Karin Lykke-Hartmann, who is appointed Distinguished Senior Innovator at Aarhus University. https://lnkd.in/d9CY5sjM

CEO and founder of Notify Therapeutics Karin Lykke-Hartmann receives the Else Kai Sass-prize 2024 for her ability to convert raw biomedical research into something which is intended to benefit patients. Reach out to learn more! https://lnkd.in/dzxU4Ciw

We are thrilled to announce that Julie Feld Madsen has joined Notify Therapeutics as a research scientist 👏 We are excited to work with Julie, a true follicle expert, and her expertise in this area is very valuable for our R&D work. Proud to say: The Best#team#ever, Notify Therapeutics , Joakim Nguyen Sørensen , Peter Mouritzen , Jean-Pierre Gotteland , Thien Duc Tran , Henrik Stage Nanna Nymark Graugaard , Kristina Byskov and Julie Feld Madsen #Innovation#Infertility#women's health. Welcome Julie 🌟

We are thrilled to announce that Nanna Nymark Graugaard and Kristina Byskov has joined Notify Therapeutics as research assistant and senior scientist, respectively 👏 We are thrilled to work with Nanna and Kristina for our innovation towards helping infertile women, not benefitting from today’s hormone treatment and their expertise in this area make them very valuable additions to our team. The Best#team#ever, Notify Therapeutics , Joakim Nguyen Sørensen , Peter Mouritzen , Jean-Pierre Gotteland , Thien Duc Tran , Henrik Stage Nanna Nymark Graugaard and Kristina Byskov #Innovation#Infertility#women's health. Welcome, Nanna and Kristina! 🌟

Metric
Company Name	Notify Therapeutics
Symbol
MSH ID	COM:NOTIFYTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	notifytherapeutics.com
LinkedIn	notifytherapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

NOTI

COM:NOTIFYTHERAPEUTICS

Notify Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue